Robert Deucher, MD
Internal Medicine · Southern Pines, NCNPI 1922042662
Payments from drug & device makers
Across 208 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$540
- Pfizer$377
- Amgen$244
- Novartis$182
- Radius Health, Inc.$171
- Lilly USA, LLC$153
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,02199%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $540 |
| Pfizer | 24 | $377 |
| Amgen | 17 | $244 |
| Novartis | 16 | $182 |
| Radius Health, Inc. | 10 | $171 |
| Lilly USA, LLC | 10 | $153 |
| Boehringer Ingelheim | 9 | $136 |
| Idorsia Pharmaceuticals US Inc | 7 | $114 |
| Otsuka America Pharmaceutical, Inc. | 5 | $112 |
| AstraZeneca | 7 | $100 |
| Avanir Pharmaceuticals, Inc. | 7 | $99 |
| Amarin Pharma, Inc. | 6 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Merck | 4 | $60 |
| Abbott | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 4 | $53 |
| Insulet Corporation | 2 | $53 |
| Johnson & Johnson | 3 | $52 |
| AbbVie | 3 | $51 |
| Corium, LLC | 3 | $47 |
| Aytu Biopharma, Inc. | 3 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Senseonics, Incorporated | 1 | $20 |
| Phadia US Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
| Medtronic | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$3,041 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 163 | $207,384 |
| EliquisApixaban | 204 | $163,830 |
| JardianceEmpagliflozin | 150 | $145,634 |
| XareltoRivaroxaban | 44 | $56,422 |
| NuedextaDextromethorphan Hbr/Quinidine | 30 | $49,287 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $45,550 |
| LinzessLinaclotide | 50 | $36,938 |
| TrulicityDulaglutide | 27 | $25,574 |
| FarxigaDapagliflozin Propanediol | 28 | $24,977 |
| RybelsusSemaglutide | 22 | $24,026 |
| ProliaDenosumab | 13 | $22,591 |
| JanuviaSitagliptin Phosphate | 23 | $21,977 |
| MounjaroTirzepatide | 18 | $20,405 |
| EntrestoSacubitril/Valsartan | 16 | $18,130 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $17,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $540 | $231,410185 claims |
| PfizerEliquis | $377 | $163,830204 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $136 | $159,518179 claims |
| Johnson & JohnsonXarelto | $52 | $56,42244 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $99 | $49,28730 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $153 | $45,97845 claims |
| AbbVieLinzess, Synthroid | $51 | $40,44598 claims |
| AstraZenecaFarxiga | $100 | $24,97728 claims |
| AmgenProlia | $244 | $22,59113 claims |
| MerckJanuvia | $60 | $21,97723 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant | $72 | $19,87930 claims |
| NovartisEntresto | $182 | $18,13016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Southern Pines
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.